Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Comparison Chart Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Real-time Estimate Cboe BZX
Other stock markets
 10:38:52 2024-06-10 am EDT 		5-day change 1st Jan Change
3.015 USD +7.68% Intraday chart for Esperion Therapeutics, Inc. +36.38% +2.17%
May. 22 Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
May. 20 Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Compared values

Sector Change 5d. change 1st Jan change 1-year change 5-years change Capi. ST MT LT
ESPERION THERAPEUTICS, INC.
Other Pharmaceuticals
+9.83%+36.38%+2.17%+148.37%-93.90% 530M
Bullish
Neutral
Bullish

Technical Rankings Surperformance

  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. Charts Esperion Therapeutics, Inc.
  5. Comparison Chart